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Abstract
Major depressive disorder (MDD) is a complex and multi-factorial disorder. Although genetic factors and other
molecular aspects of MDD have been widely studied, the underlying pathological mechanisms are still mostly
unknown. We sought to investigate the pathophysiology of MDD by identifying and characterising serum
molecular differences and their correlation to symptom severity in ﬁrst onset, antidepressant drug-naïve
MDD patients. We performed an exploratory molecular proﬁling study on serum samples of MDD patients
and controls using multiplex immunoassay and label-free liquid chromatography mass spectrometry in data
independent mode (LC-MSE). We included two independent cohorts of ﬁrst onset, antidepressant drug-naïve
MDD patients (n=23 and 15) and matched controls (n=42 and 21) in our study in order to validate the results.
The main outcome included the following list of circulatory molecules changing and/or correlating to symptom
severity: angiotensin-converting enzyme, acute phase proteins (e.g. ferritin and serotransferrin), brain-derived
neurotrophic factor, complement component C4-B, cortisol, cytokines (e.g. macrophage migration inhibitory
factor and interleukin-16), extracellular newly identiﬁed receptor for advanced glycosylation end products-
binding protein, growth hormone and superoxide dismutase-1. This study provides evidence of an increased
pro-inﬂammatory and oxidative stress response, followed by a hyperactivation of the HPA-axis in the acute
stages of ﬁrst onset MDD, as well as a dysregulation in growth factor pathways. These ﬁndings help to elucidate
MDD related pathways in more detail and further studies may lead to identiﬁcation of novel drug targets,
including components of the inﬂammatory and oxidative stress response.
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Introduction
Studies of major depressive disorder (MDD) are
complicated due to the complexity and multi-factorial
nature of this disorder. The potential role of genetic
factors and other molecular aspects of MDD have been
investigated, such as hypothalamic- pituitary- adrenal
(HPA) axis dysfunction [reviewed in (Fava and Kendler,
2000)], association with immune response [reviewed in
(Raedler, 2011)] and metabolic disorders [reviewed in
(Gans, 2006)]. However, the underlying pathological
mechanisms are still mostly unknown.
Traditionally, psychiatric diseases have been regarded
as brain disorders. However, it is not possible to obtain
brain samples from living patients. Furthermore, post-
mortem brain tissue analyses would not allow for the
study of dynamic changes such as those which can
occur before and after treatment with ADs. However,
some insight into brain function in living patients has
been obtained using neuroimaging techniques, neuro-
psychological assessment tools and pharmacological
challenge tests. In addition, recent studies have begun
to study brain function through the analysis of peripheral
body ﬂuids, such as blood plasma, serum or cells. The
study of serum or plasma molecules in cases of psychi-
atric disease is rational since many such molecules are
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known to affect or reﬂect brain function. These include
circulating neuroendocrine hormones such as insulin,
leptin, adrenocorticotrophic hormone (ACTH) and
cortisol, along with numerous inﬂammatory factors in-
cluding interleukin (IL)-1, IL-6, IL-18, interferon-gamma
and tumour necrosis factor (TNF) alpha. Furthermore,
the association between inﬂammation and MDD has
been supported by the fact that cytokine treatment of
hepatitis C and certain cancer types frequently induce
depressive symptoms as side effects (Capuron et al.,
2000; Lotrich, 2009). Therefore, there is a precedent for
looking at inﬂammatory and other circulating factors in
the early phases of MDD as performed in this study.
This study has two main aims: (1) to identify and
characterise serum molecular differences that are asso-
ciated with the disease onset in ﬁrst onset, antidepressant
drug-naïve MDD patients compared to controls and
(2) to identify serum molecules associated with symptom
severity of MDD. If successful, the latter will help to
strengthen the case for the role of these proteins as puta-
tive markers for the disorder. For this purpose, serum
samples of MDD patients and control subjects were sub-
jected to molecular proﬁling analyses using multiplex
immunoassay and liquid chromatography mass
spectrometry in data independent mode (LC-MSE).
This multiplex proﬁling approach was used to eliminate
variability across individual measurements, thereby
allowing reliable identiﬁcation of molecules, which are
co-regulated within and across molecular pathways. The
platform targets the immune molecules and HPA axis
hormones mentioned above, along with other molecular
classes including growth factors, transport molecules
and components of the clotting cascade, which may also
be involved. An additional strength of this study is that
the analysis of ﬁrst onset, antidepressant drug-naïve
MDD patients, thus eliminating the potential confound-
ing inﬂuence of chronic AD medication, has not been per-
formed previously.
Method
Study participants and sample collection
The study included two consecutive cohorts collected ap-
proximately one year apart at the Department of Psy-
chiatry, University of Magdeburg, Germany (Table 1A
and B). Cohort 1 consisted of 42 healthy controls
(40.57±11.17 years) and 23 patients (40.83±11.64 years),
Table 1. Demographic details of ﬁrst onset MDD patients and matched control subjects of (a) cohort 1 and (b) cohort 2
Multiplex immunoassay LC-MSE
Control Patient p-value Control Patient p-value
(a) Cohort 1
Number 42 23 21 15
Gender (m/f) 18/24 11/12 0.7962F 12/9 10/5 0.7317F
Age (yr) 40.57±11.17 40.83±11.64 0.9015W 41.14±12.67 39.53±13.09 0.4308W
BMI (kg/m2) 25.17±3.54 25.20±6.07 0.7316W 24.87±3.03 25.80±5.42 0.9744W
Smoking (yes/no) 8/34 10/13 0.0458F 5/16 9/6 0.0410F
HAMD NA 21.96±11.64 NA NA 21.75±6.23 NA
(b) Cohort 2
Number 21 15 21 15
Gender (m/f) 7/14 3/12 0.4682F 7/14 3/12 0.4682F
Age (yr) 36.00±10.18 36.93±9.22 0.4791W 36.00±10.18 36.93±9.22 0.4791W
BMI (kg/m2) 23.15±3.47 23.12±4.00 0.5106W 23.15±3.47 23.12±4.00 0.5106W
Smoking (yes/no) 6/15 8/7 0.1753F 6/15 8/7 0.1753F
HAMD NA 17.33±6.84 NA NA 17.33±6.84 NA
Cohorts combined
Number 63 38 42 30
Gender (m/f) 25/38 14/24 0.8349F 19/23 13/17 1.0000F
Age (yr) 39.05±10.98 39.29±10.79 0.8828W 38.57±11.65 38.23±11.20 0.8908W
BMI (kg/m2) 24.50±3.62 24.38±5.08 0.4833W 24.01±3.33 24.46±4.88 0.9272W
Smoking (yes/no) 14/49 18/20 0.0144F 11/31 17/13 0.0139F
HAMD NA 20.05±6.78 NA NA 19.50±6.89 NA
The table shows number of samples, gender, age, body mass index (BMI), smoking and Hamilton Depression Scale (HAMD) scores of
patients and controls used in the multiplex immunoassay and LC-MSE study. Age, BMI and HAMD values are shown in average ±S.D.
Note that the LC-MSE proﬁling was limited to a subset of samples from cohort 1 due to reduced availability, whereas all samples from
cohort 2 were analysed.
F=Fisher’s exact test. W=Wilcoxon rank sum test.
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and cohort 2 was comprised of 21 healthy controls
(36.00±10.18 years) and 15 patients (36.93±9.22 years).
Controls were identiﬁed using M.I.N.I. (Mini Inter-
national Neuropsychiatric Interview - German Version
5.0.0). All MDD patients from cohort 1 and 2 were diag-
nosed with ﬁrst onset MDD and were antidepressant
drug-naïve at the time of serum sample collection and
none were taking other medications such as glucocorti-
coids. All patients met the Diagnostic and Statistical
Manual of Mental Disorders, 4th Edition, Text Revision
(DSM-IV-TR) criteria for MDD and clinical tests including
administration of the Hamilton Depression Scale
(HAMD) assessment were performed by psychiatrists
under good clinical practice-compliance to minimise
variability. MDD patients with other psychiatric co-
morbidities were excluded and controls were screened for
personal or family history of neuropsychiatric disorders
using M.I.N.I. (German Version 5.0.0) and excluded if
these were present. Patients and controls were free of
acute and chronic infections, allergies, autoimmune
diseases, cancer or systemic diseases as determined by
self-report, doctors’ report or by physical examination.
In addition, patients and controlswere excludedwith a his-
tory of immune diseases, immunomodulatory treatment,
cancer, chronic terminal disease, cardiovascular disorders,
diabetes mellitus, substance abuse, and severe trauma or
with clinical or paraclinical ﬁndings indicative of these dis-
orders. All subjects gave informedwritten consent. Clinical
investigationswere conductedaccording to theDeclaration
of Helsinki, and the University of Magdeburg ethical com-
mittee approved the study.
Potential differences in demographic characteristics
between patients and matched control subjects were as-
sessed using either the Mann Whitney U test [age and
body mass index (BMI)] or Fisher’s exact test (gender
and smoking).
Blood samples were collected from all participants
after an overnight fast at around 08:00 a.m. on each
occasion in the Department of Psychiatry, University
of Magdeburg, Germany under the supervision of
Dr Johann Steiner by venous puncture into S-Monovette
7.5 ml serum tubes (Sarstedt, Germany). Serum was pre-
pared according to standard protocols by leaving the
samples at room temperature for 2 h to allow coagulation
followed by centrifugation at 1000 g for 5min at 21 °C to
remove the clotted material. The resulting supernatants
were stored at −80 °C in Low Binding Eppendorf tubes
(Germany) prior to analysis. A quality control (QC) sam-
ple was prepared from a pool of spare serum samples and
split into aliquots for use in the LC-MSE study to evaluate
technical reproducibility.
Multiplexed immunoassay proﬁling
For cohort 1 and 2, a total of 190 molecules were mea-
sured in sera (200–250 μl) using the HumanMAP® v 1.0
platform in a CLIA-certiﬁed laboratory (Myriad-RBM,
USA; Supplementary Table 1) (Bertenshaw et al., 2008).
This panel of assays targets inﬂammatory, metabolic,
hormonal and neurotrophic pathways and has been
applied successfully in previous studies of psychiatric
disorders such as schizophrenia and MDD (Domenici
et al., 2010; Schwarz et al., 2010).
LC-MSE analysis
Sera were processed in random order to avoid potential
sequential biases and were depleted of the 14 most
abundant proteins using MARS14 (Agilent, USA) on a
ÄKTA™ puriﬁer UPC 10 chromatography system
(GE Healthcare, UK) using afﬁnity chromatography as
reported previously (Jaros et al., 2013). This was carried
out to increase detection of a higher number of serum
proteins, which are normally masked by the higher
abundance proteins. QC samples were comprised of one
randomly selected sample, which was divided into multi-
ple aliquots. These were added to each sample prep-
aration batch and prepared and analysed in parallel
with the normal samples. Buffer exchange into 50mM
ammonium bicarbonate was carried out using spin col-
umns (Millipore, USA) with a 5 kDa molecular cut-off.
Disulﬁde bonds on proteins were reduced using 100mM
dithiothreitol (Sigma, UK) for 30min at 60 °C and free
sulfhydryl moieties were alkylated with 200mM iodo-
acetamide (Sigma) in the dark at room temperature for
30min. The proteins were enzymatically digested using
porcine trypsin (Promega, USA), at a ratio of 1:50 (w/w
trypsin/protein) for 17 h at 37 °C. Reactions were stopped
by addition of 8.8 M HCl (ratio=1:60) to each sample and
samples were stored at −80 °C.
LC-MSE proﬁling was carried out in expression
mode using a Waters quadrupole time-of-ﬂight (QToF)
Premier mass spectrometer (Waters, UK), as described
previously (Levin et al., 2010). Resulting data were
processed using the ProteinLynx Global Server (PLGS)
v.2.4 (Waters) and Rosetta Inpharmatics Biosoftware
Elucidator v.3.3 (USA) (Krishnamurthy et al., 2013). The
human Swiss-Prot database (v.57, 20332 entries) search
analysis was performed using PLGS with the ion account-
ing algorithm described previously (Li et al., 2009). The
criteria for protein identiﬁcation were set to53 fragment
ions/peptide, and 57 fragment ions and 2 peptides/pro-
tein. The maximum false identiﬁcation rate was 4%
using a randomised version of the database. Only pep-
tides detected in both replicates and in 60% of samples
were included in further analysis. Search results were
imported into Elucidator for annotation of aligned fea-
tures, resulting in a matrix that included intensities for
each sample and peptide.
Statistics
Comparisons between groups were based on the non-
parametric Mann Whitney U test for both cohorts and
analysis platforms. To identify molecular signature
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differences between MDD and controls, analysis of
co-variance (ANCOVA) was performed using smoking
as co-variate. For ANCOVA, all variables were log10-
transformed to approximate normal distributions.
Patients and control subjects from both cohorts, used
for multiplex immunoassay and LC-MSE studies, did
not differ signiﬁcantly in age, gender or BMI. However,
patients and controls differed in the ratio of smokers
to non-smokers (data not shown) in both cohorts.
Therefore, smoking was used as a co-variate in the ana-
lyses of molecular differences using both measuring
platforms. No signiﬁcant associations between HAMD
scores and patient demographics were found (data not
shown) in any of the cohorts. To identify markers of
symptom severity as well as signiﬁcant associations
between demographics and HAMD scores, we applied
non-parametric Spearman correlation (for age and BMI)
and non-parametric Mann Whitney U (for gender and
smoking) tests. P-values <0.05 were considered signiﬁ-
cant. Molecules showing a trend to signiﬁcance (p<0.10)
were included as these constituted potential consistency
between the cohorts and platforms for validation pur-
poses. Cohorts were not only analysed singly, but values
of both cohorts (cohort 1 & 2) were also combined,
normalised for batch effect and analysed, to increase the
statistical power of the analyses by increasing sample
numbers. All analyses were performed using the statisti-
cal software package R 2.12 (RDC Team, 2009) and
Prism version 5 (GraphPad Software, USA).
Fold change (FC) values were calculated for each mol-
ecule as the average values of patients divided by those of
controls (MDD/C). Resulting values <1.0 were multiplied
by −1/X (where Z is the value) to give a negative FC.
For multiplex immunoassay analyses, values under
the detection limit were replaced as described previously
(Stelzhammer et al., 2011). Furthermore, molecules,
which had more than 40% of values outside the detection
limit within a group were not included in the ﬁnal
list of changed molecules. For all LC-MSE studies, co-
efﬁcients of variation (CVs) were calculated using
the QC measured intensities. The overall study CV was
calculated as the mean of total protein CVs to assess tech-
nical variation. Signiﬁcant analytes identiﬁed in the
analysis of cohort 1 were used to carry out a predictive
test on cohort 2 and the correct classiﬁcation rate
determined.
Results
Multiplex immunoassay
Molecules altered in major depressive disorder compared
to controls
Multiplexed immunoassay analysis of cohort 1 and 2 sera
resulted in the identiﬁcation of 11 proteins, which showed
reproducible differences between MDD patients and
controls in both cohorts (Table 2; see Supplementary
Table 2 for complete listing of signiﬁcantly altered ana-
lytes in cohorts 1 and 2). The use of two cohorts provided
a validation of the ﬁndings and the combination of both
cohorts increased the statistical power of the ﬁndings.
Six of these proteins [extracellular newly identiﬁed
RAGE-binding protein (EN-RAGE), ferritin, interleukin-1
receptor antagonist (IL-1ra), IL-16, macrophage migration
inhibitory factor (MIF) and tenascin-C) were signiﬁcantly
increased and one [angiotensin-converting enzyme
(ACE)] was signiﬁcantly decreased in both cohorts. Two
proteins [serotransferrin (decreased) and superoxide
dismutase 1 (SOD-1; increased)] were altered signiﬁcantly
in cohort 2 and trended to signiﬁcance (P<0.1) in
Table 2. Multiplex immunoassay proﬁling results of serum from ﬁrst onsetMDD patients vs. healthy controls (patient/control) (cohort 1:
23 MDD vs. 42 HC; cohort 2: 15 MDD vs. 21 HC; and both cohorts combined)
Molecule name Acc.No. FC
Cohort 1 Cohort 2 Cohort 1 & 2
p-value p-value p-value
Ferritin P02794 3.70|4.59|3.36 0.0017 0.0047 <0.0001
MIF P14174 1.65|2.32|2.74 <0.0001 0.0064 <0.0001
EN-RAGE P80511 2.45|2.53|2.24 <0.0001 0.0016 <0.0001
Superoxide dismutase 1 P00441 1.11|1.50|1.58 *0.0611 0.0081 0.0011
Interleukin-1 receptor antagonist P18510 1.44|1.46|1.56 0.0013 0.0101 <0.0001
Interleukin-16 Q14005 1.40|1.20|1.27 0.0001 0.0303 <0.0001
Tenascin-C P24821 1.35|1.34|1.27 0.0086 0.0034 0.0002
Brain-derived neurotrophic factor Q9BYY7 1.15|1.16|1.16 *0.0902 *0.0983 0.0219
Angiotensin-converting enzyme P12821 −1.13|−1.20|−1.16 0.0297 0.0237 0.0016
Serotransferrin P13726 −1.14|−1.17|−1.26 *0.0522 0.0315 0.0037
Growth hormone P01241 −3.12|−4.90|−3.78 *0.0754 *0.0673 0.0100
The table includes Uniprot accession numbers (Acc.No.), fold changes (FC; cohort 1|cohort 2|cohort 1 & 2), p-values (Mann Whitney U
test), and ANCOVA [bold text=analytes signiﬁcant, *=analyte trending to signiﬁcance (>0.05 and <0.1)] after correction for smoking
covariate. Only molecules, which showed biological validation by being changed in both cohorts were included in this table.
EN-RAGE, Extracellular newly identiﬁed RAGE-binding protein; MIF, Macrophage migration inhibitory factor.
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cohort 1. EN-RAGE and ferritin showed the most marked
differences as both were increased by more than 2-fold in
MDD patients compared to controls in both cohorts
(Fig. 1). Two other proteins [brain-derived neurotrophic
factor (BDNF; increased) and growth hormone (GH;
decreased)] were also included as they trended to sig-
niﬁcance in both cohorts and both were signiﬁcant in
the combined cohort. GH was decreased by more than
3-fold in MDD subjects compared to controls when both
cohorts were combined (Fig. 1). All molecules which
were either trending to signiﬁcance in one or both cohorts
showed signiﬁcant changes after combining both cohorts
due to the increase in statistical power. Cortisol was not
changing or trending to signiﬁcance in cohort 2, and
therefore not included in Table 2, it was signiﬁcantly
increased in cohort 1 (FC: 1.67, p-value: 0.0072) and
when both cohorts were combined (FC: 2.93, p-value:
0.0047).
Multivariate classiﬁcation revealed that the combined
panel of 11 differentially expressed analytes (ACE,
EN-RAGE, ferritin, IL-1ra, IL-16, MIF, tenascin C, sero-
transferrin, SOD-1, BDNF and GH) found in cohort 1
(MDD=23, control=42) produced a separation between
MDD (N=15) and control subjects (N=21) in cohort 2
with a correct classiﬁcation rate of 89% using linear discri-
minant analysis. The sensitivity was 0.89 and the speciﬁ-
city was 0.95.
Symptom severity (multiplex immunoassay)
The second part of the study attempted to identify as-
sociations between molecule levels and HAMD scores
at the time of sample collection. Of the 11 molecules
that were present at different levels between ﬁrst onset
MDD patients and controls in cohort 1 and 2, two of
these, MIF and SOD-1, were signiﬁcantly positively corre-
lated with HAMD scores in cohort 1 and ACE trended
(p<0.10) to a negative correlation (Table 3). None of the
molecules showed a correlation to HAMD scores that
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Fig. 1. Multiplex immunoassay result examples. The ﬁgure includes (a) EN-RAGE, (b) ferritin, and (c) growth hormone changes in
ﬁrst onset MDD patients (MDD) vs. healthy controls (HC) (cohort 1: 23 MDD vs. 42 HC; cohort 2: 15 MDD vs. 21 HC, and both
cohorts combined). When cohorts 1 and 2 were combined, values were normalised between both cohorts for the comparison
between MDDs and HCs.
Table 3. Multiplex immunoassay symptom severity markers
Molecule name
Cohort 1
p-value rs
Angiotensin-converting enzyme 0.0732 0.39
Macrophage migration inhibitory factor 0.0495 0.42
Superoxide dismutase 1 0.0323 0.46
The table shows signiﬁcant associations (bold text) between mol-
ecular levels and HAMD scores at the time of sampling in co-
hort 1 (23 MDD). The results for cohort 2 (15 MDD) and both
cohorts combined are not shown as these showed no signiﬁcant
correlations. The table includes p-value (Spearman’s correlation
test), correlation coefﬁcient (rs).
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was reproducible in both cohorts. Issues with repro-
ducibility may be traced back to too subtle interactions
between molecule intensities and HAMD scores, which
could not be statistically shown due to limitations in
sample size.
LC-MSE
The CV of QC samples after LC-MSE analysis was
25.47±18.67 in cohort 1 and 18.59±16.50 in cohort 2.
Overall, 8517 and 9546 peptides were detected which
corresponded to 430 and 408 proteins in cohort 1 and 2,
respectively. In total, 169 proteins overlapped and were
detected in both cohorts.
Molecules altered in major depressive disorder compared
to controls
LC-MSE analysis resulted in identiﬁcation of two mol-
ecules (ceruloplasmin and haptoglobin-related protein),
which showed reproducible changes in sera from patients
and controls in cohorts 1 and 2 (Table 4). Although
haptoglobin-related protein was only trending to signiﬁ-
cance in cohort 1, it was signiﬁcantly changing in cohort 2
and when values of this molecule were combined from
cohorts 1 & 2.
Symptom severity (LC-MSE)
The greatest correlation was seen in cohort 2 as two mol-
ecules (complement factor C4-B and haptoglobin-related
protein) were positively correlated and two (plasminogen
and ceruloplasmin) were negatively correlated with
HAMD scores (Table 5). However, only complement fac-
tor C4-B showed a reproducible correlation with symp-
tom severity in both cohorts (Table 5). The correlation
for plasminogen did not reach signiﬁcance although it
showed a trend (p=0.0550). When combining both
cohorts none of these molecules interacted with HAMD
scores. Again, issues with reproducibility may be traced
back to too subtle interactions between molecule intensi-
ties and HAMD scores, which could not be statistically
shown due to limitations in sample sizes.
Discussion
This is the ﬁrst study to investigate molecular proﬁling
differences, as well as symptom severity markers, in
serum of two cohorts of ﬁrst onset, antidepressant
drug-naïve MDD patients. The ﬁndings from analysis of
samples from cohorts 1 and 2 are most likely to be asso-
ciated with the underlying pathophysiology of MDD as
these were replicated and not biased by AD medication
since all patients were antidepressant-naïve at the time
Table 4. LC-MSE proﬁling results of serum from ﬁrst onset MDD patients vs. healthy controls (HC) (cohort 1: 15 MDD vs. 21 HC; cohort
2: 15 MDD vs. 21 HC; and both cohorts combined)
Name Acc No FC
Cohort 1 Cohort 2 Cohort 1 & 2
Peptides CV SCp-value p-value p-value
HPR P00739 1.60|2.21|1.90 *0.0698 0.0047 0.0014 12|14 1.23|14.62 33.05|40.23
CP P00450 −1.09|−1.13|−1.11 0.0028 0.0059 0.0001 225|281 5.98|27.11 88.92|92.58
The table includes abbreviated protein names (haptoglobin-related protein=HPR; ceruloplasmin=CP), Uniprot accession numbers
(Acc.No.), fold changes (FC; cohort 1|cohort 2|cohort 1 & 2), p-values (Mann Whitney U test), and ANCOVA p-value (A; cohort 1|co-
hort 2|cohort 1 & 2; bold values are signiﬁcant) analysis results after correction of co-variate (smoking), peptide number (peptides;
cohort 1|cohort 2), internal coefﬁcient of variance (CV; cohort 1|cohort 2) and sequence coverage (SC; cohort 1|cohort 2). Only mole-
cules were included in this table, which showed biological validation by being changed in both cohorts.
Table 5. LC-MSE symptom severity markers
Molecule name Acc.No.
Cohort 1 Cohort 2
p-value rs p-value rs
Complement C4-B P0C0L5 0.0287 0.55 0.0058 0.45
Plasminogen P00747 0.0386 −0.52 0.0550 −0.32
Ceruloplasmin P00450 – – 0.0199 −0.39
Haptoglobin-related protein P00739 – – 0.0085 0.43
The table shows signiﬁcant associations (in bold text) between molecular levels and HAMD scores at the time of sampling in cohort 1
(15 MDD) and cohort 2 (15 MDD). The results for both cohorts combined are not shown as none of these associations were signiﬁcant.
The table includes Uniprot accession numbers (Acc.No.), p-value (Spearman’s correlation test), and correlation coefﬁcient (rs).
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of sample collection. This is not the case with most pre-
vious studies, which used similar approaches (Domenici
et al., 2010). Drug-free and drug-naïve samples are ob-
viously difﬁcult to obtain in psychiatric research.
This study showed evidence of pro-inﬂammatory
changes (i.e. ceruloplasmin, EN-RAGE, ferritin, hapto-
globin-related protein, IL-1 ra, IL-16, MIF, serotransferrin
and tenascin-C) in ﬁrst onset MDD patients. Although
there has been already accumulating evidence that an in-
creased immune response has an inﬂuence on the patho-
physiology of MDD and may even induce depressive
symptoms (Maes, 2011), reproducible changes found in
inﬂammatory markers, such as ferritin and EN-RAGE,
have not been shown before in ﬁrst onset MDD patients.
Ferritin is a multifunctional protein involved in iron
metabolism and has been shown to be elevated during
inﬂammation (Alkhateeb and Connor, 2013). It is a posi-
tive acute phase protein (APP), which tends to increase
in response to inﬂammation and is part of the innate
immune system (Calandra and Roger, 2003). We showed
that this protein was increased by more than 3-fold in
both of the ﬁrst onset MDD patient cohorts compared
to healthy controls. Although the relationship between
ferritin and MDD has rarely been studied before,
Huang and Lee (2007) have shown that haemodialysis
patients with MDD had signiﬁcantly higher levels of
ferritin than patients without MDD and that increased
ferritin levels predicted depressive symptoms (Huang
and Lee, 2007).
Ferritin has also been shown to have antioxidant
properties (Alkhateeb and Connor, 2013), due to its
ferroxidase activity and iron storage capacity. There is
some evidence that the activation of immune responses
may cause oxidative stress and overproduction of reactive
oxygen species (ROS) and antioxidative enzymes (Bilici
et al., 2001). Furthermore, there is mounting evidence
that ROS are involved in the development of different
forms of human pathologies such as MDD (Herken
et al., 2007). This is consistent with our ﬁnding that
SOD-1 was increased in both MDD cohorts and this
was correlated with symptom severity in cohort 1.
Similar to this study, Bilici et al., showed that SOD-1
levels were increased in MDD patients compared to
healthy controls and these were normalised after
three months of AD treatment (Bilici et al., 2001). Taken
together, these ﬁndings suggest that an increased im-
mune response and oxidative stress may be involved in
the early stages of MDD (Fig. 2).
Previous studies have found that antidepressant
treatment is associated with a decrease in inﬂammatory
markers [reviewed by (Miller et al., 2009)]. Furthermore,
clinical trials investigating the effects of anti-
inﬂammatory treatment with Cox-2 inhibitors as add-on
therapy to AD treatments have demonstrated positive
effects (Muller, 2010; Raison et al., 2013). However,
further evaluation of the effects of Cox-2 inhibition and
anti-inﬂammatory therapy for MDD is required. For
example, further studies should be carried out on the
role of ferritin in MDD, considering the marked effects
seen on this protein in the current study.
We also identiﬁed changes in the levels of other APPs
in ﬁrst onset MDD patients. Interestingly, increased levels
of the positive APP, complement component C4-B, corre-
lated with symptom severity in both cohorts. Further-
more, the haptoglobin-related protein (Nielsen et al.,
2006) was increased in both cohorts. We also found a
reproducible decrease in the negative APP serotransferrin
in ﬁrst onset MDD patients. These results suggest that an
increased innate immune response, particularly including
Immune response Oxidative stress
Acute phase proteins:
Pro-inflammatory markers:
Antioxidants:
HPA-axis
RAS
• Ferritin ↑
• EN-RAGE ↑
• Cortisol ↑
• ACE ↓
Growth factors
Neurotransmitter
metabolism
• BDNF ↑
• GH ↓
• MIF ↑
• IL-16 ↑
• Tenascin-C ↑
• Ferritin ↑
• SOD-1 ↑• Serotransferrin ↓
• Haptoglobin-related protein ↑
• Ceruloplasmin ↓
Fig. 2. Summary of molecular changes in this study. This
study showed evidence of an activated immune response in
ﬁrst onset, antidepressant drug-naïve MDD patients, due to
increases in positive acute phase proteins (APP) ferritin and
haptoglobin-related protein and negative APP serotransferrin,
as well as pro-inﬂammatory changes of extracellular newly
identiﬁed RAGE-binding protein (EN-RAGE), macrophage
migration inhibitory factor (MIF), IL-16 and tenascin-C. The
multifunctional ferritin has immunological and anti-oxidant
properties. These ﬁndings suggest increased oxidative stress in
ﬁrst onset MDD compared to controls which is further
supported by increased levels of superoxide dismutase 1
(SOD-1). Changes in immune response were associated with
effects on the hypothalamic-pituitary-adrenal (HPA) axis and
renin-angiotensin-system (RAS), as shown by increased cortisol
and decreased angiotensin converting enzyme (ACE) levels.
These pathways may also be linked to effects on growth factors
[brain derived neurotrophic factor (BDNF) and growth
hormone (GH)] and neurotransmitter metabolism, which are
hypothesised to be contributing factors to MDD. All molecular
changes found in this study are indicated in black in this
ﬁgure. Hypothesised links, which are solely based on literature
ﬁndings are indicated in grey.
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the APP ferritin, is present early on in the disease course
of MDD. This is consistent with the ﬁndings of a previous
study, which showed increased levels of the positive
APPs haptoglobin and alpha-1-antichymotrypsin in
MDD patients, which correlated with symptom severity
(Joyce et al., 1992).
We found that ceruloplasmin was decreased in cohort 1
and 2, which correlated with symptom severity in
cohort 2. However, as it is a positive APP, this result
does not agree with the other APP ﬁndings already dis-
cussed above. Interestingly, ceruloplasmin was pre-
viously reported to be increased in schizophrenia (Wolf
et al., 2006; Morera et al., 2007). As we have seen the
opposite regulation in ﬁrst onset MDD patients, the
potential of ceruloplasmin as a differential candidate
marker between MDD and schizophrenia should be
assessed in future studies.
As mentioned above, general alterations of inﬂamma-
tory cytokines and other inﬂammation-related proteins
have been previously described in blood cerebrospinal
ﬂuid and post-mortem studies of MDD patients [re-
viewed in (Maes et al., 1995; Raedler, 2011)]. In particular,
our ﬁnding of increased levels of the pro-inﬂammatory
proteins EN-RAGE, IL-16, MIF and tenascin-C support
the case that there is an increase in inﬂammatory response
in ﬁrst onset MDD patients (Simon et al., 2008). Further-
more, MIF showed a signiﬁcant positive correlation to
symptom severity, indicating that patients with higher
MIF levels had a higher symptom severity at the time
of sample collection. Increased levels of MIF have also
been previously linked to MDD (Musil et al., 2011). There-
fore, MIF is a promising candidate in the neuro-immune
interplay that may link depressive symptoms, altered im-
mune state and HPA-axis dysregulation (Fig. 2).
Several studies have implicated altered HPA axis
dysfunction in MDD pathophysiology, as increased
stress vulnerability has been associated with MDD and
acts as a trigger on the HPA axis, inﬂammatory and endo-
crine components of the disorder (Bartolomucci and
Leopardi, 2009). Although normal activation of the
HPA-axis is important for appropriate responses to acute
stressors, chronic dysfunction of the HPA axis may result
in long-lasting problems (Raedler, 2011), including effects
on the immune system, mood, emotion and energy
storage and expenditure (Engelmann et al., 2004). Most
studies show a hyperfunction of the HPA axis in MDD
patients, as shown by the presence of elevated circulating
cortisol, corticotropin releasing hormone and ACTH
(Nemeroff et al., 1984; Charlton et al., 1987; Roy et al.,
1987; Breier et al., 1988). In this study, cortisol was sign-
iﬁcantly increased in cohort 1 and in the combined
cohorts. In cohort 2, increased levels of cortisol showed
a trend towards signiﬁcance. However, this required con-
trol for smoking as a confounding factor. The effect of
smoking on cortisol levels, as well as other inﬂammatory
markers (e.g. c-reactive protein, IL-6 and TNF alpha),
should also be considered in future MDD studies as it
has been shown to have an inﬂuence on the levels of
these molecules (Steptoe and Ussher, 2006).
Interestingly, ACE is linked to HPA activity as part
of the renin-angiotensin-system (RAS), and was de-
creased in ﬁrst onset MDD. ACE was found to be chang-
ing in cohorts 1 and 2, and decreased levels of
ACE correlated with symptom severity in cohort 1. This
result supports previous studies suggesting that the
RAS is connected to the aetiology of MDD (Saab et al.,
2007) and that the change is present early on in the
disorder.
Peripheral inﬂammatory markers, including inﬂamma-
tory cytokines, have been shown to have the ability
to cross the blood–brain barrier, thereby affecting brain
function [reviewed by (Wichers and Maes, 2002;
Yarlagadda et al., 2009). These factors are also involved
in multiple aspects of MDD pathophysiology, including
neurotransmitter metabolism, neuroendocrine function
and neural plasticity (Miller et al., 2009).
Previous studies have shown that BDNF levels
are decreased in MDD (Sen et al., 2008), leading to the
‘neurotrophin hypothesis of depression’. In line with
this hypothesis, other studies have shown that BDNF
levels are increased after electroconvulsive stimuli or
AD medication in both animal models (Angelucci et al.,
2002) and MDD patient (Brunoni et al., 2008; Sen et al.,
2008). We found that BDNF levels were increased in
both cohorts, which is in contrast to previous literature
results. However, as this is one of the ﬁrst studies to
investigate this protein in ﬁrst onset, antidepressant
drug-naïve MDD patients, the present ﬁndings suggest
the potential presence of counter-regulatory protective
mechanism in the early stages of the disorder. This is con-
sistent with the current ﬁnding of increased levels of the
anti-inﬂammatory cytokine IL-1 ra, which may indicate
a counter-regulatory mechanism in response to the elev-
ation of the pro-inﬂammatory cytokines.
Limitations
Molecular studies in psychiatric research are generally
limited by sample size, which increases the risk of false-
positive results. This was certainly a limitation in the
present study given the large number of analytes mea-
sured. However, we were able to test two independent
cohorts, which strengthened the results. Nevertheless,
the current ﬁndings should be considered as an explora-
tory study and further validation is required.
Although over 400 proteins were detected in cohorts 1
and 2, the serum proteome comprises several thousand
proteins, which also include a variety of differential post-
translational modiﬁcations of common core proteins. This
limited the number of proteins that could be identiﬁed
using this method. To increase this capacity, future stu-
dies could use complementary LC-MS platforms and pro-
tein modiﬁcation-speciﬁc investigations (Brewis and
Brennan, 2010).
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It should also be noted that the ﬁnding of no change
a given molecule does not necessarily mean that it is
not a contributor to the aetiology of MDD. For example,
it could be the case that an early increase in one or
more molecules initiates a cascade of actions and then
these molecules return to normal levels.
The focus of this study was to investigate molecular
signatures related to MDD. Further studies are needed
to compare our ﬁndings to known changes in other
psychiatric disorders, such as schizophrenia and bipolar
disorder, to establish the speciﬁcity of these markers to
MDD.
Conclusions
This comprehensive study has shown multiple changes
in ﬁrst onset, antidepressant drug-naïve MDD patients,
some of which have been reported previously in MDD
research. We have also identiﬁed novel molecular
and proteomic changes, which could help to elucidate
MDD affected pathways in more detail and may be useful
for the early detection of MDD. We found strong
evidence of a link between an increased inﬂammatory
response (i.e. ferritin, EN-RAGE, ceruloplasmin, IL-16,
MIF, serotransferrin and tenascin-C) and oxidative stress
(i.e. ferritin and SOD-1), as well as a hyperactive
HPA-axis (i.e. cortisol), RAS (i.e. ACE) and changes in
growth factors (i.e. BDNF and growth hormone), con-
sistent with literature hypotheses. However, further
studies are warranted to determine whether these
molecular changes are causative factors in MDD or if
they are an adaptive response to disease-related
changes in the brain or periphery. Such studies of these
pathways in MDD could lead to identiﬁcation of novel
drug targets.
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